Cancer jab can eradicate entire tumours in patients, trial shows

Cancer jab can eradicate entire tumours in patients, trial shows Jab brought ‘unprecedentedly strong responses’ in patients whose disease had become resistant to chemotherapy and immunotherapy Andrew Gregory Health editor, in Chicago Sat 30 May 2026 19.00 CEST Prefer the Guardian on Google Doctors have hailed “unprecedented” trial results that show a triple-action cancer jab can eradicate entire tumours in patients. In an international trial spanning 11 countries, the injection was offered to patients whose cancer had spread or come back and whose disease had failed to respond to other treatments. The jab, called amivantamab, shrank the tumours of more than a third of patients, with dramatic changes seen within weeks. In 15 of them, doctors found the drug had melted away their tumours altogether. Kevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, London (ICR), said: “These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy. “This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking.” Harrington, also a consultant oncologist at the Royal Marsden NHS foundation trust, added: “This treatment has the potential to benefit many thousands of patients each year.” The results will be presented on Sunday in Chicago at the world’s largest cancer conference, the annual meeting of the American Society of Clinical Oncology (Asco). In the trial, 102 patients with head and neck cancer, the world’s sixth most common cancer, were given the jab. Tumours shrank or disappeared completely in 43 patients, including 28 whose tumours shrank significantly and 15 who saw them eradicated entirely. Researchers said the injection had also shown similar results in patients with lung cancer. Amivantamab, developed by Johnson & Johnson, is now being evaluated in about 60 clinical trials, primarily for lung cancer, but also for colorectal, brain and gastric cancers. The smart jab targets cancer in three ways. It blocks both EGFR (epidermal growth factor receptor), a protein that helps tumours grow, and MET, a pathway that cancer cells often use to escape treatment. It also helps activate the immune system to attack the tumour. One of the first patients to benefit was Carl Walsh, 56, who was diagnosed with tongue cancer in May 2024 and joined the OrigAMI-4 trial at the Royal Marsden in July 2025. “I was initially treated with both chemotherapy and immunotherapy, which unfortunately were not successful,” he said. “At that point, I was recommended for the OrigAMI-4 trial. I’m now on my 17th cycle of treatment and I’m very pleased with the progress so far.” Unlike many cancer treatments, amivantamab is given as a tiny jab under the skin rather than via an intravenous drip, making treatment quicker and more convenient for patients and much easier to deliver in outpatient clinics. Most side-effects of the treatment, given once every three weeks, were mild to moderate, with fewer than one in 10 patients forced to stop their treatment. Walsh, from Birmingham, said: “I now feel able to live a normal life. Before starting the trial, I struggled to speak properly and found eating difficult because of the swelling and pain. “Since beginning treatment, the swelling has reduced significantly, and my pain levels have improved considerably. I’m also no longer experiencing the same life-impacting side-effects that I had during chemotherapy.” He added: “When things were at their worst I was eating soup, rice pudding, tins of ravioli and spaghetti and many, many omelettes, all augmented by three prescribed nutritional milk drinks a day. I lost quite a bit of weight. “After only two cycles of the treatment my diet started to return to normal and I was eating a full diet after six months. The thing I enjoyed most was the first big steak. My speech is completely back to normal and at work I speak regularly on headsets without problems.” Researchers also highlighted that the trial focused on people with head and neck cancers that did not include those with human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma. That is particularly significant, they said, since head and neck cancers not caused by HPV are usually harder to treat, making progress in this group hugely important. Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working. Prof Kristian Helin, the chief executive of the ICR, said: “This study demonstrates how the development of new treatments through rigorous cancer research may lead to meaningful advances, even for patients with very limited treatment options. “Achieving this level of tumour response and encouraging survival outcomes in such a challenging‑to‑treat group represents a significant step forward.” https://www.theguardian.com/science/2026/may/30/cancer-jab-can-eradicate-entire-tumours-in-patients-trial-shows?CMP=fb_gu&utm_medium=Social&utm_source=Facebook#Echobox=1780211275

On the Origin of Species By Charles Darwin

https://www.vliz.be/docs/Zeecijfers/Origin_of_Species.pdf

free tools to make every thing

https://tinywow.com/

Achieve More With Less Find Free Software, Apps, Tools, and Other Resources For Professional Growth.

https://mrfreetools.com/

Wild animals in our city

MY AI video

Jitsi Meet

Jitsi Meet Free Video Conferencing Solutions Go ahead, video chat with the whole team. In fact, invite everyone you know. Jitsi Meet is a fully encrypted, 100% open source video conferencing solution that you can use all day, every day, for free — with no account needed. What else can you do with Jitsi Meet? Share your desktop, presentations, and more Invite users to a conference via a simple, custom URL Edit documents together using Etherpad Pick fun meeting URLs for every meeting Trade messages and emojis while you video conference, with integrated chat https://jitsi.org

Impossible Places | World's Most Dangerous Extreme Homes on Earth You Can’t Believe They Exist

https://youtu.be/SBla5PMlRWI?si=Wzc__AFJ8lehjHmF

Impossible Places | 25 World's Most Dangerous Roads That Challenge Every Driver | 4K Travel

Study associates stress with impaired memory, reduced brain size in middle age

https://news.uthscsa.edu/study-finds-stress-can-impair-memory-reduce-brain-size-in-middle-age/ Adults in their 40s and 50s with higher levels of cortisol—a hormone linked to stress—performed worse on memory and other cognitive tasks than peers of the same age with average cortisol levels, research found. Higher cortisol in the blood also was associated with smaller brain volumes, according to the study, published Oct. 24 in Neurology, the medical journal of the American Academy of Neurology. “In our quest to understand cognitive aging, one of the factors attracting significant interest and concern is the increasing stress of modern life,” said study senior author Sudha Seshadri, M.D., professor of neurology at UT Health San Antonio and founding director of the university’s Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases. “One of the things we know in animals is that stress can lead to cognitive decline. In this study, higher morning cortisol levels in a large sample of people were associated with worse brain structure and cognition.” The cognitive data are from 2,231 participants in the Framingham Heart Study, for which Dr. Seshadri is a senior investigator; 2,018 participants also underwent magnetic resonance imaging (MRI) to measure brain volume. The team included Framingham collaborators at Harvard Medical School; the National Heart, Lung, and Blood Institute; Boston University School of Medicine; the University of California, Davis, at Sacramento; and UT Health San Antonio

Conduit

Conduit is an app from Psiphon that allows users to voluntarily turn their device (mobile/computer) into a proxy node,h elping people in censored countries bypass internet blocks. By running the app in the background, your device routes encrypted traffic to Psiphon's network, giving others open access to the internet without revealing your personal information. How Conduit Internet Works: Proxy Node/Gateways: Your device acts as a bridge (tunnel) connecting other users to Psiphon's network. Censorship Breakthrough: When someone in a country with strict censorship connects, their traffic is routed through your "Conduit Station" to bypass restrictions. Security: Traffic is end-to-end encrypted, and the app does not log your personal information or browsing history. Usage: Conduit is lightweight, runs in the background, and allows you to set bandwidth limits. Conduit is thus a tool to promote "Internet Freedom" and is not a traditional VPN for personal anonymization, but a decentralized solution for sharing internet access. https://play.google.com/store/apps/details?id=ca.psiphon.conduit&pcampaignid=web_share&utm_source=conduit_site&pli=1 https://apps.microsoft.com/detail/9p89sj33m3jp?utm_source=conduit_site&hl=sv-SE&gl=SE https://conduit.psiphon.ca/fa/macos